Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Immune intervention with anti-CD3 in diabetes

Autoimmune processes that destroy insulin-producing cells in the pancreas cause type 1 diabetes. To prevent the disease, autoreactive immune cells need to be suppressed or eliminated without deleterious side effects. Results from a phase 2 clinical trial take steps in this direction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A path forward for type 1 diabetes treatment.

Katie Ris

References

  1. The Canadian-European Randomized Control Trial Group. Diabetes 37, 1574–1582 (1988).

  2. Rother, K.I. & Harlan, D.M. J. Clin. Invest. 114, 877–883 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Herold, K.C. et al. N. Engl. J. Med. 346, 1692–1698 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. Chatenoud, L. et al. N. Engl. J. Med. 352, 2598–2608 (2005).

    Article  PubMed  Google Scholar 

  5. Sutherland, D.E. et al. Trans. Assoc. Am. Physicians 97, 80–87 (1984).

    CAS  PubMed  Google Scholar 

  6. Chatenoud, L., Thervet, E., Primo, J. & Bach, J.F. Proc. Natl. Acad. Sci. USA 91, 123–127 (1994).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Herold, K.C. et al. Diabetes 54, 1763–1769 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 128, 517–523 (1998).

  9. Swinnen, L.J. et al. N. Engl. J. Med. 323, 1723–1728 (1990).

    Article  CAS  PubMed  Google Scholar 

  10. Smith, J.A., Tso, J.Y., Clark, M.R., Cole, M.S. & Bluestone, J.A. J. Exp. Med. 185, 1413–1422 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Smith, J.A., Tang, Q. & Bluestone, J.A. J. Immunol. 160, 4841–4849 (1998).

    CAS  PubMed  Google Scholar 

  12. Walker, M.R. et al. J. Clin. Invest. 112, 1437–1443 (2003).

    Article  CAS  PubMed  Google Scholar 

  13. Homann, D. et al. Immunity 11, 463–472 (1999).

    Article  CAS  PubMed  Google Scholar 

  14. Skyler, J.S. et al. Diabetes Care 28, 1068–1076 (2005).

    Article  CAS  PubMed  Google Scholar 

  15. Nakayama, M. et al. Nature 435, 220–223 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. von Herrath, M.G. & Harrison, L.C. Nat. Rev. Immunol. 3, 223–232 (2003).

    Article  CAS  PubMed  Google Scholar 

  17. Harlan, D.M. Endocrinology 145, 463–466 (2004).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harlan, D., von Herrath, M. Immune intervention with anti-CD3 in diabetes. Nat Med 11, 716–718 (2005). https://doi.org/10.1038/nm0705-716

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0705-716

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing